BNET Industries
AstraZeneca Plc. is in the Pharma Industry
Latest News and Analysis
Yangtze River Delta Developing Huge R&D Base for Drug Companies
ChinaBio Today submits: [Editor’s note: The following article originates from coverage of the BioBay Investor Forum 2008, presented by ChinaBio on August 27/28 in Suzhou. It was hosted by BioBay, the life science park in Suzhou. The article is reprinted with permission from Interfax China. Interfax China pharma news...
Tough Projections for Big Pharmas: Drug Revenues Don't Look Promising
Derek Lowe submits: Well, today’s subject isn’t a cheerful data set, but it certainly deserves some thought. Over at Pharmalot, Ed Silverman has some data from consulting firm AVOS Life Sciences, which has sat down to estimate how well various drug companies will do with revenue from new drugs...
Time to Invest in Pharmaceuticals?
Howard Sun submits: The prices of many pharmaceutical companies have been beaten down by Wall Street in recent months. With companies like Pfizer PFE, Schering-Plough SGP and Bristol-Myers Squibb BMY reaching lower lows, one has to wonder when the pain will end as these companies are now significantly undervalued. The...
Zacks Analyst Interview Highlights: Syngenta, Monsanto, GlaxoSmithKline, Sanofi-Aventis and AstraZeneca
CHICAGO -- Zacks.com releases the latest Analyst Interview. Today's interview is with senior analyst Santiago Burgaleta, who discusses Syngenta (NYSE: SYT), Monsanto (NYSE: MON). GlaxoSmithKline (NYSE: GSK), Sanofi-Aventis (NYSE: SNY) and AstraZeneca (NYSE: AZN).
Zacks Analyst Interview Highlights: Pfizer, Abbott Labs, AstraZeneca, Sanofi-Aventis and GlaxoSmithKline
CHICAGO -- Zacks.com releases the latest Analyst Interview. Today's interview is with senior analyst Jason Napodano, who discusses Pfizer (NYSE: PFE), Abbott Labs (NYSE: ABT), AstraZeneca (NYSE: AZN), Sanofi-Aventis (NYSE: SNY) and GlaxoSmithKline (NYSE: GSK).
Business news in brief
IN THE REGION Drug-design firm raises long-term operating capital Locus Pharmaceuticals Inc., Blue Bell, said it had raised $30.2 million from investors. The computational drug-design and development company said Novartis Bioventures Ltd., Prism Venture Partners and HBM BioVentures Cayman Ltd. led the financing. Other participants included S.R. One...
Research and Markets: Discover How Companies Such As Astrazeneca, Novartis and Sanofi-Aventis Invest Their Money in Their Mid-Level Product Teams 'Inside Marketing Mid-Tier Pharmaceutical Brands'
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c39113) has announced the addition of Marketing Mid-Tier Pharmaceutical Brands: Winning Resources for Near-Blockbusters to their offering.
New Research Examines How Successful the Pipeline Enhancement Process has been in Practice for four 'Mega Corporations' - AstraZeneca, GlaxoSmithKline, Pfizer, and Sanofi-Aventis
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c32166) has announced the addition of Mega Corporation Pipelines: A Postmerger Analysis to their offering.
Research and Markets: Astrazeneca, Glaxosmithkline , Pfizer, and Sanofi-Aventis the Four Pharmaceutical 'Mega Corporations' Have All Emerged During the First Half of the Decade
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c32166) has announced the addition of Mega Corporation Pipelines: A Postmerger Analysis to their offering.
Research and Markets: Read company analysis and market share of the top ten players in the Cardiovascular area, including Pfizer, Sanofi-Aventis, Merck, Novartis, AstraZeneca and Bristol-Myers Squibb
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c31693) has announced the addition of The Latin American Cardiovascular Market Outlook to 2010 to their offering.
AstraZeneca, Sanofi-Aventis, Novo Nordisk, Abbott Laboratories and TAP Gain Ground as Novartis Holds onto No.1 Rank with Managed Care Executives, Cognet-X Inc. Announces
FEASTERVILLE, Pa. -- Novartis Pharmaceuticals Corp. retained its first-place ranking while several other pharmaceutical companies achieved higher ratings in meeting the overall needs of managed care pharmacy executives, Cognet-X Inc. reported today.
Additional Resources
Main Movers
UP Barclays 167p (up 20.5p, 13.99 per cent) Relieved by Citigroup rescue; cheered by new Fed moves to tackle mortgage debts. Royal Bank of Scotland 53.6p (up 2.8p, 5.51 per cent) Sector rallies; Citigroup says "buy". BSS 271.75p (up 13.5p, 5.23...
Teva Announces Agreement on Generic Pulmicort Respules® Patent Challenge
JERUSALEM -- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced that its subsidiary, Teva Pharmaceuticals USA, Inc., has signed an agreement with AstraZeneca to settle patent litigation involving Teva's U.S. generic version of AstraZeneca's Pulmicort Budesonide Respules[R] including all claims for patent infringement and damages. Teva launched its generic budesonide...
Abraxis BioScience Announces Agreement to Re-Acquire Exclusive U.S. Rights to ABRAXANE; Company Highlights Plans to Initiate Nine Pivotal Registrational Trials in 2009
* Abraxis receives agreements from regulatory authorities to proceed with six Phase 3 and one pivotal Phase 2 registrational trials of ABRAXANE in breast, lung, melanoma, pancreatic, ovarian and gastric cancer * Current results in an ongoing Phase 2 clinical study in patients with pancreatic cancer are encouraging...
Rolls-Royce, BAE and AstraZeneca to cut jobs
Briefing almost 600 job cuts have been announced in the UK defence, aerospace and drug industries. Rolls-Royce said it would axe up to 2,000 jobs, including 140 in the UK, after reviewing the impact of the current economic "uncertainties". AstraZeneca said it planned to cut 1,400...
GSK to take on AstraZeneca portfolio
Business in brief healthcare The expansion of GlaxoSmithKline's consumer healthcare division continued yesterday when the UK's biggest drug firm announced it is spending 146m on its rival AstraZeneca's Swedish over-the-counter medicine business. The move is part of the group's change of strategy under a new chief...
Main Movers
UP Experian 329.25p (up 22.75p, 7.42 per cent) Investors welcome robust interim results. ICAP 244.25p (up 14.25p, 6.2 per cent) Bargain-hunters move to capitalise on recent losses. Fresnillo 100.4p (up 1.4p, 1.41 per cent) Bucks sector trend after the price of...
Par Pharmaceutical Halts Shipment of Budesonide Inhalation Suspension
WOODCLIFF LAKE, N.J., Nov. 20 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. today announced that the U.S. District Court for the District of New Jersey last night granted AstraZeneca Pharmaceuticals' motion for a temporary restraining order TRO halting sales of Teva's generic Pulmicort RespulesR budesonide inhaled solution. In...
Beacon Equity Issues Technical Trade Alerts on Drug Manufacturers: NVS, JNJ, PFE, GSK, ABT, AZN
DALLAS, Nov. 20 /PRNewswire/ -- BeaconEquity.com announces the availability of Trade Alerts on stocks making news today. Investors can view all of the daily trading notes for free by visiting: http://www.beaconequity.com/m Today's Trade Alerts include: Novartis AG , Johnson & Johnson , Pfizer Inc. ,...
Teva Provides Update on Generic Pulmicort Respules® Launch
JERUSALEM -- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announces that further to its press release dated November 19, 2008, the United States District Court for the District of New Jersey has granted AstraZeneca's request for a temporary order restraining further sales of Teva's generic version of AstraZeneca's Pulmicort Budesonide Respules[R]...
- Next »
- page 1 of 1
- « Previous
Sort byClose
View by Content TypeClose
View Related Content by Tag Close
Industry Transcripts by Seeking Alpha
-
Indevus Pharmaceuticals, Inc. F4Q08 (Qtr End 09/30/08) Earnings Call Transcript
on Nov 25, 2008about IDEV
-
Noven Pharmaceuticals, Inc. Q3 2008 Earnings Call Transcript
on Nov 24, 2008about NOVN
-
XenoPort, Inc. Q3 2008 Earnings Call Transcript
on Nov 24, 2008about XNPT
-
Repligen Corporation F2Q09 (Qtr End 09/30/08) Earnings Call Transcript
on Nov 24, 2008about RGEN
-
Omrix Biopharmaceuticals, Inc. Q3 2008 Earnings Call Transcript
on Nov 24, 2008about OMRI
AstraZeneca Plc. Company Info
NAICS Code
Pharmaceutical Preparation Manufacturing: 325412
